Clobex is a drug owned by Galderma Laboratories Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 03, 2022. Details of Clobex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7700081 | Foaming compositions for hair care |
Jan, 2022
(3 years ago) |
Expired
|
| US8066975 | Foaming composition for washing and treating hair and/or scalp based on an active principle |
Jun, 2019
(5 years ago) |
Expired
|
| US8066976 | Foaming compositions for hair care |
Jun, 2019
(5 years ago) |
Expired
|
| US7316810 | Foaming composition for washing and treating hair and/or scalp based on an active principle |
Jun, 2019
(5 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Clobex's patents.
Latest Legal Activities on Clobex's Patents
Given below is the list of recent legal activities going on the following patents of Clobex.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 01 Jan, 2024 | US8066975 |
| Expire Patent Critical | 01 Jan, 2024 | US8066976 |
| Maintenance Fee Reminder Mailed Critical | 17 Jul, 2023 | US8066975 |
| Maintenance Fee Reminder Mailed Critical | 17 Jul, 2023 | US8066976 |
| Expire Patent Critical | 23 May, 2022 | US7700081 |
| Maintenance Fee Reminder Mailed Critical | 06 Dec, 2021 | US7700081 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 May, 2019 | US8066975 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 May, 2019 | US8066976 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2017 | US7700081 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Nov, 2011 | US8066975 |
US patents provide insights into the exclusivity only within the United States, but Clobex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Clobex's family patents as well as insights into ongoing legal events on those patents.
Clobex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Clobex's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 03, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Clobex Generic API suppliers:
Clobetasol Propionate is the generic name for the brand Clobex. 35 different companies have already filed for the generic of Clobex, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Clobex's generic
How can I launch a generic of Clobex before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Clobex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Clobex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Clobex -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.0005 | 27 Mar, 2006 | 1 | 04 Dec, 2008 | 22 Sep, 2017 | Eligible |
| 0.0005 | 29 Sep, 2008 | 1 | 16 Jun, 2011 | 24 Mar, 2018 | Eligible |
| 0.0005 | 09 Jan, 2008 | 1 | 07 Jun, 2011 | 17 Jun, 2019 | Non-Forfeiture |
Alternative Brands for Clobex
Clobex which is used for treating scalp psoriasis and moderate to severe plaque psoriasis., has several other brand drugs in the same treatment category and using the same active ingredient (Clobetasol Propionate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Primus Pharms |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Clobetasol Propionate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Formosa |
| ||
| Norvium Bioscience |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clobetasol Propionate, Clobex's active ingredient. Check the complete list of approved generic manufacturers for Clobex
About Clobex
Clobex is a drug owned by Galderma Laboratories Inc. It is used for treating scalp psoriasis and moderate to severe plaque psoriasis. Clobex uses Clobetasol Propionate as an active ingredient. Clobex was launched by Galderma Labs in 2004.
Approval Date:
Clobex was approved by FDA for market use on 05 February, 2004.
Active Ingredient:
Clobex uses Clobetasol Propionate as the active ingredient. Check out other Drugs and Companies using Clobetasol Propionate ingredient
Treatment:
Clobex is used for treating scalp psoriasis and moderate to severe plaque psoriasis.
Dosage:
Clobex is available in shampoo form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | SHAMPOO | Prescription | TOPICAL |
Clobex is a drug owned by Galderma Laboratories Lp. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 24, 2018. Details of Clobex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5990100 | Composition and method for treatment of psoriasis |
Mar, 2018
(7 years ago) |
Expired
|
| US5972920 | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
Feb, 2018
(7 years ago) |
Expired
|
| US6106848 | Topically applicable O/W emulsions having high glycol content and at least one biologically active agent |
Sep, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Clobex's patents.
Latest Legal Activities on Clobex's Patents
Given below is the list of recent legal activities going on the following patents of Clobex.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Expire Patent Critical | 01 Jan, 2024 | US8066975 |
| Expire Patent Critical | 01 Jan, 2024 | US8066976 |
| Maintenance Fee Reminder Mailed Critical | 17 Jul, 2023 | US8066975 |
| Maintenance Fee Reminder Mailed Critical | 17 Jul, 2023 | US8066976 |
| Expire Patent Critical | 23 May, 2022 | US7700081 |
| Maintenance Fee Reminder Mailed Critical | 06 Dec, 2021 | US7700081 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 May, 2019 | US8066975 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 May, 2019 | US8066976 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2017 | US7700081 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Nov, 2011 | US8066975 |
US patents provide insights into the exclusivity only within the United States, but Clobex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Clobex's family patents as well as insights into ongoing legal events on those patents.
Clobex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Clobex's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 24, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Clobex Generic API suppliers:
Clobetasol Propionate is the generic name for the brand Clobex. 35 different companies have already filed for the generic of Clobex, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Clobex's generic
How can I launch a generic of Clobex before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Clobex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Clobex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Clobex -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.0005 | 27 Mar, 2006 | 1 | 04 Dec, 2008 | 22 Sep, 2017 | Eligible |
| 0.0005 | 29 Sep, 2008 | 1 | 16 Jun, 2011 | 24 Mar, 2018 | Eligible |
| 0.0005 | 09 Jan, 2008 | 1 | 07 Jun, 2011 | 17 Jun, 2019 | Non-Forfeiture |
Alternative Brands for Clobex
Clobex which is used for treating scalp psoriasis and moderate to severe plaque psoriasis., has several other brand drugs in the same treatment category and using the same active ingredient (Clobetasol Propionate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Primus Pharms |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Clobetasol Propionate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Formosa |
| ||
| Norvium Bioscience |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clobetasol Propionate, Clobex's active ingredient. Check the complete list of approved generic manufacturers for Clobex
About Clobex
Clobex is a drug owned by Galderma Laboratories Lp. It is used for treating scalp psoriasis and moderate to severe plaque psoriasis. Clobex uses Clobetasol Propionate as an active ingredient. Clobex was launched by Galderma Labs Lp in 2005.
Approval Date:
Clobex was approved by FDA for market use on 27 October, 2005.
Active Ingredient:
Clobex uses Clobetasol Propionate as the active ingredient. Check out other Drugs and Companies using Clobetasol Propionate ingredient
Treatment:
Clobex is used for treating scalp psoriasis and moderate to severe plaque psoriasis.
Dosage:
Clobex is available in lotion form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | LOTION | Prescription | TOPICAL |